The use of circulating, cell-free DNA (cfDNA) is rapidly evolving in the clinical landscape and is one of the fastest-growing areas in recent years. It offers tremendous clinical potential as a screening method for tumor, cancer, fetal DNA studies, disease progression, treatment response, and more. Circulating DNA extraction is often challenging as they are found in low quantities, and accurate methods are needed to isolate the less abundant cfDNA with higher sensitivity and specificity. Rapid, reliable, and high throughput methodologies are needed for widespread adoption and implementation of cfDNA-based diagnostics in clinical care.
Omega Bio-tek has developed a fully automated solution to extract cfDNA from up to 10 mL samples in 2.75 hours when integrated on Hamilton’s Microlab® STAR™ platform. The system is scalable and can extract from sample volumes ranging from 1-10 mL without any hardware modification or additional accessories on the Hamilton workstation. Omega’s high throughput workflow allows flexible sample inputs and low elution volumes for isolating inhibitor-free, concentrated cfDNA for use in various downstream applications.
Join Omega Bio-tek’s Dr. Kiranmai Durvasula and Hamilton’s Dr. Kristina Klette as we explore the automation of Omega’s cfDNA kit on the Hamilton Microlab STAR platform as well as look at other possibilities:
- Significance of cfDNA
- Circulating tumor DNA (ctDNA) vs cfDNA
- Ways to enrich ctDNA
We will hold an open Q&A session to answer your questions. Bring them to the live event or submit them through the registration form.